JP2014210824A5 - - Google Patents

Download PDF

Info

Publication number
JP2014210824A5
JP2014210824A5 JP2014168689A JP2014168689A JP2014210824A5 JP 2014210824 A5 JP2014210824 A5 JP 2014210824A5 JP 2014168689 A JP2014168689 A JP 2014168689A JP 2014168689 A JP2014168689 A JP 2014168689A JP 2014210824 A5 JP2014210824 A5 JP 2014210824A5
Authority
JP
Japan
Prior art keywords
gastritis
treatment
prostaglandin
prevention
agonist component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2014168689A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014210824A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014210824A publication Critical patent/JP2014210824A/ja
Publication of JP2014210824A5 publication Critical patent/JP2014210824A5/ja
Ceased legal-status Critical Current

Links

JP2014168689A 2006-12-18 2014-08-21 胃腸疾患の治療方法および組成物 Ceased JP2014210824A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87044406P 2006-12-18 2006-12-18
US60/870,444 2006-12-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2009543060A Division JP2010513551A (ja) 2006-12-18 2007-12-11 胃腸疾患の治療方法および組成物

Publications (2)

Publication Number Publication Date
JP2014210824A JP2014210824A (ja) 2014-11-13
JP2014210824A5 true JP2014210824A5 (enExample) 2014-12-25

Family

ID=39059771

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009543060A Ceased JP2010513551A (ja) 2006-12-18 2007-12-11 胃腸疾患の治療方法および組成物
JP2014168689A Ceased JP2014210824A (ja) 2006-12-18 2014-08-21 胃腸疾患の治療方法および組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2009543060A Ceased JP2010513551A (ja) 2006-12-18 2007-12-11 胃腸疾患の治療方法および組成物

Country Status (7)

Country Link
US (1) US20100081631A1 (enExample)
EP (3) EP2465506A1 (enExample)
JP (2) JP2010513551A (enExample)
AU (1) AU2007334038A1 (enExample)
BR (1) BRPI0721067A2 (enExample)
CA (1) CA2690273A1 (enExample)
WO (1) WO2008076703A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7855226B2 (en) 2003-02-11 2010-12-21 Allergan, Inc. Treatment of inflammatory bowel disease
US8580954B2 (en) 2006-03-28 2013-11-12 Hospira, Inc. Formulations of low dose diclofenac and beta-cyclodextrin
US20090012165A1 (en) * 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
AU2011282549A1 (en) * 2010-07-30 2013-02-28 Allergan, Inc. Compounds and methods for skin repair
US20120142684A1 (en) * 2010-12-02 2012-06-07 Allergan, Inc. Compounds and methods for skin repair
RU2586040C1 (ru) * 2014-12-25 2016-06-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия" Министерства Здравоохранения Российской Федерации (ГБОУ ВПО НижГМА Минздрава России) Способ диагностики идиопатической язвенной болезни желудка и двенадцатиперстной кишки
EP3307747A4 (en) 2015-06-12 2019-02-27 Simon Fraser University AMID LINKED EP4 AGONIST BISPHOSPHONATE COMPOUNDS AND USES THEREOF
NL2018407B1 (en) * 2017-02-22 2018-09-17 Skytree B V Improved process and apparatus for the removal of metabolic carbon dioxide from a confined space

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL110298A (en) 1993-07-13 1999-04-11 Brann Mark Robert Identification of ligands by selective amplification of cells transfected with receptors
WO2000015608A1 (fr) 1998-09-14 2000-03-23 Ono Pharmaceutical Co., Ltd. Derives e de phenyl-prostaglandine a substitution-φ et medicaments les contenant comme ingredient actif
MXPA03004623A (es) 2000-11-27 2003-09-05 Pfizer Prod Inc Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis.
WO2003074483A1 (en) * 2002-03-05 2003-09-12 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
US7855226B2 (en) 2003-02-11 2010-12-21 Allergan, Inc. Treatment of inflammatory bowel disease
WO2006047476A2 (en) * 2004-10-26 2006-05-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
US7893107B2 (en) * 2005-11-30 2011-02-22 Allergan, Inc. Therapeutic methods using prostaglandin EP4 agonist components
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists

Similar Documents

Publication Publication Date Title
JP2014210824A5 (enExample)
HK1218560A1 (zh) 组成与方法
EA201690962A1 (ru) Составы
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
JP2013014622A5 (enExample)
JP2013525444A5 (enExample)
EA031157B9 (ru) Вводимая перорально кортикостероидная композиция
DOP2017000294A (es) Unidad de dosificación orodispersable que contiene un componente estetrol
JP2013032389A5 (enExample)
EP3932907A3 (en) Dextromethorphan analogs and combinations of deuterated dextromethorphan and nortriptyline for use in treating agitation and/or aggression
EA201001781A1 (ru) Применение гликозаминогликанов для перорального введения и композиции гликозаминогликанов
JP2015525757A5 (enExample)
BRPI0511327B8 (pt) combinações de glicopirrolato e agonistas do adrenorreceptor beta2
MX2018003975A (es) Combinacion de glicosaminoglicanos y un agente antacido y sus composiciones.
JP2014218522A5 (enExample)
SA517390550B1 (ar) وحدة جرعة قابلة للتفتت في الفم تتضمن مكون أستيترول
JP2014221827A5 (enExample)
EP2956149A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HELICOBACTER PYLORI
PH12015502406A1 (en) Orally administrable pharmaceutical composition for prevention or treatment of dry eye syndrome, comprising rebamipide or prodrug thereof
JP2017505809A5 (enExample)
WO2016168553A8 (en) Deuterated obeticholic acid
JP2012528856A5 (enExample)
WO2016040814A3 (en) Disulfide polymers and methods of use
EA201691034A1 (ru) Композиции в твердой форме с замедленным высвобождением для перорального введения
JP2009505991A5 (enExample)